E Fund Management Co. Ltd. trimmed its position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) by 45.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 8,829 shares of the company’s stock after selling 7,446 shares during the period. E Fund Management Co. Ltd.’s holdings in Dyne Therapeutics were worth $312,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Concurrent Investment Advisors LLC acquired a new position in Dyne Therapeutics in the 1st quarter valued at about $573,000. Sei Investments Co. acquired a new position in Dyne Therapeutics in the 1st quarter valued at about $693,000. Rafferty Asset Management LLC boosted its holdings in Dyne Therapeutics by 17.7% in the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after purchasing an additional 24,632 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in Dyne Therapeutics in the 1st quarter valued at about $810,000. Finally, Commodore Capital LP acquired a new position in Dyne Therapeutics in the 4th quarter valued at about $11,970,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.
Dyne Therapeutics Stock Down 0.8 %
Shares of DYN opened at $34.34 on Thursday. Dyne Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $47.45. The firm’s 50 day moving average price is $41.38 and its 200 day moving average price is $33.47. The company has a market cap of $3.00 billion, a P/E ratio of -8.65 and a beta of 1.07.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on DYN shares. Oppenheimer reiterated an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday. JPMorgan Chase & Co. upped their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. Guggenheim upped their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $51.40.
View Our Latest Analysis on Dyne Therapeutics
Insider Buying and Selling at Dyne Therapeutics
In other Dyne Therapeutics news, COO Susanna Gatti High sold 10,163 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $35.33, for a total value of $359,058.79. Following the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, COO Susanna Gatti High sold 10,163 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $35.33, for a total value of $359,058.79. Following the transaction, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Cox bought 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The disclosure for this purchase can be found here. Insiders own 20.77% of the company’s stock.
Dyne Therapeutics Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- How to Invest in Blue Chip Stocks
- How Much Can You Make in Stocks in One Month?
- Investing In Automotive Stocks
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Evaluate a Stock Before Buying
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.